MDMA pharmacokinetics: A population and physiologically based pharmacokinetics model-informed analysis.
CPT: pharmacometrics & systems pharmacology February 1, 2025 Marilyn A. Huestis, William B Smith, Cathrine Leonowens et al. 3 citations
Midomafetamine (3,4-methylenedioxymethamphetamine [MDMA]) is under the U.S. Food and Drug Administration review for treatment of post-traumatic stress disorder in adults. MDMA is metabolized by CYP2D6 and is a strong inhibitor of CYP2D6, as well as a weak inhibitor of renal transporters MATE1, OCT1, and OCT2. A pharmacokinetic phase I study was conducted to evaluate the effects of food on MDMA...